Search Results - "WITTEBOL, Shulamit"

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma by Broijl, Annemiek, Kersten, Marie-José, Alemayehu, Wendimagegn Ghidey, Levin, Mark-David, de Weerdt, Okke, Vellenga, Edo, Meijer, Ellen, Wittebol, Shulamit, Tanis, Bea C, Cornelisse, Petra B, Stevens-Kroef, Marian, Bos, Gerard M J, Wijermans, Pierre W, Lokhorst, Henk, Sonneveld, Pieter

Get full text

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia by DEENIK, Wendy, JANSSEN, Jeroen J. W. M, SONNEVELD, Pieter, VAN MARWIJK KOOY, Marinus, WITTEBOL, Shulamit, WILLEMZE, Roelof, WIJERMANS, Pierre W, BEVERLOO, H. Berna, LÖWENBERG, Bob, VALK, Peter J. M, OSSENKOPPELE, Gert J, CORNELISSEN, Jan J, VAN DER HOLT, Bronno, VERHOEF, Gregor E. G, SMIT, Willem M, KERSTEN, Marie José, DAENEN, Simon M. G. J, VERDONCK, Leo F, FERRANT, Augustin, SCHATTENBERG, Anton V. M. B

“…In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was…”
Get full text

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison by Cornelissen, Jan J., van der Holt, Bronno, Verhoef, Gregor E.G., van 't Veer, Mars B., van Oers, Marinus H.J., Schouten, Harry C., Ossenkoppele, Gert, Sonneveld, Pieter, Maertens, Johan, van Marwijk Kooy, Marinus, Schaafsma, Martijn R., Wijermans, Pierre W., Biesma, Douwe H., Wittebol, Shulamit, Voogt, Paul J., Baars, Joke W., Zachée, Pierre, Verdonck, Leo F., Löwenberg, Bob, Dekker, Adriaan W.

“…While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hematopoietic stem cell transplantation (allo-SCT) is still…”
Get full text

Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial by Kater, Arnon P., Van Oers, Marinus H.J. H.J., Norden, Yvette, Liu, Roberto D., Schipperus, Martin R., Chamuleau, Martine, Nijland, Marcel, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, Croon-de Boer, Fransien, Wittebol, Shulamit, Kerst, Martijn, Marijt, Willem, Posthuma, Ward, Raymakers, Reinier, Schaafsma, Ron, Dobber, Johan, Kersting, Sabina, Levin, Mark-David

“…Introduction. Since publication of the pivotal CLL011 phase 3 trial, combination of chlorambucil and anti-CD20 MAb has become the standard first-line CLL…”
Get full text

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone‐refractory myeloma by Van De Donk, Niels W.C.J., Wittebol, Shulamit, Minnema, Monique C., Lokhorst, Henk M.

Get full text

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial by Sonneveld, Pieter, Scheid, Christof, van der Holt, Bronno, Jarari, Laila el, Bertsch, Uta, Salwender, Hans, Zweegman, Sonja, Vellenga, Edo, Broyl, Annemiek, Wolfgang Blau, Igor, Weisel, Katja, Wittebol, Shulamit, Bos, Gerard M.J., Stevens, Marjan, Schmidt-Wolf, Ingo GH, Pfreundschuh, Michael, Hose, Dirk, Jauch, Anna, van de Velde, Helgi, Raymakers, Reinier, Schaafsma, Martyn Ronald, Kersten, Marie Jose, van Marwijk Kooy, Marinus, Duehrsen, Ulrich, Lindemann, Hans Walter, Wijermans, Pierre W., Lokhorst, Henk, Goldschmidt, H.

“…We investigated if bortezomib during induction and maintenance improves survival in newly diagnosed Multiple Myeloma (MM). 827 eligible patients with newly…”
Get full text

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study by Segeren, Christine M., Sonneveld, Pieter, van der Holt, Bronno, Vellenga, Edo, Croockewit, Alexandra J., Verhoef, Gregor E.G., Cornelissen, Jan J., Schaafsma, Martijn R., van Oers, Marinus H.J., Wijermans, Pierre W., Fibbe, Wim E., Wittebol, Shulamit, Schouten, Harry C., Kooy, Marinus van Marwijk, Biesma, Douwe H., Baars, Joke W., Slater, Rosalyn, Steijaert, Monique M.C., Buijt, Ivon, Lokhorst, Henk M.

“…We compared the efficacy of intensified chemotherapy followed by myeloablative therapy and autologous stem cell rescue with intensified chemotherapy alone in…”
Get full text

Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma by Scheid, Christof, Sonneveld, Pieter, Schmidt-Wolf, Ingo, van der Holt, Bronno, Hielscher, Thomas, el Jarari, Laila, Bertsch, Uta, Salwender, Hans, Zweegman, Sonja, Hänel, Mathias, Vellenga, Edo, Schubert, Joerg, Blau, Igor Wolfgang, Jie, Asiong, Van de elde, Helgi, Peter, Norma, Schaafsma, Martijn, Lindemann, Walter, Kersten, Marie Jose, Duehrsen, Ulrich, Delforge, Michel, Weisel, Katja, Croockewit, Sandra, Martin, Hans, Wittebol, Shulamit, Schouten, Harry, van Marwijk-Kooy, Marinus, Wijermans, Pierre, Lokhorst, Henk M, Goldschmidt, Hartmut

“…Abstract 2396 Renal impairment is a frequent complication in patients with multiple myeloma (MM) and is correlated with an inferior prognosis. Bortezomib can…”
Get full text

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM) by Sonneveld, Pieter, Schmidt-Wolf, Ingo, van der Holt, Bronno, Jarari, Laila el, Bertsch, Uta, Salwender, Hans, Zweegman, Sonja, Vellenga, Edo, Schubert, Joerg, Blau, Igor Wolfgang, Jie, Asiong, Beverloo, Berna, Hose, Dirk, Jauch, Anna, van de Velde, Helgi, Schaafsma, Martijn, Lindemann, Walter, Kersten, Marie Jose, Duehrsen, Ulrich, Delforge, Michel, Weisel, Katja, Croockewit, Sandra, Martin, Hans, Wittebol, Shulamit, Scheid, Christof, Bos, Gerard, van Marwijk-Kooy, Marinus, Wijermans, Pierre, Lokhorst, Henk, Goldschmidt, Hartmut

“…Abstract 40 This independent trial was designed to evaluate the efficacy of bortezomib (B) during induction and maintenance on progression-free survival (PFS)…”
Get full text

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia by Deenik, Wendy, van der Holt, Bronno, Verhoef, Gregor E.G., Smit, Willem M., Kersten, Marie J., Kluin-Nelemans, Hanneke C., Verdonck, Leo F., Ferrant, Augustin, Schattenberg, Anton V. M.B., Janssen, Jeroen J. W.M., Sonneveld, Pieter, van Marwijk Kooy, Marinus, Wittebol, Shulamit, Willemze, Roelof, Wijermans, Pierre W., Westveer, Petra H.M., Beverloo, H. Berna, Valk, Peter, Löwenberg, Bob, Ossenkoppele, Gert J., Cornelissen, Jan J.

“…The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase…”
Get full text

In Vivo Tumor Dynamic Studies in Stable CLL Show an Association between CLL Turnover Rates and IgVH Mutational Status and Provide Evidence That the Bone Marrow Is Not a Major Site of Neoplastic Cell Generation by Kater, Arnon P., van Gent, Rogier, Jaspers, Annelieke, Borghans, Jose A.M., Otto, Sigrid, Ruiter, An F.C., Wittebol, Shulamit, Eldering, Eric, Van Oers, Marinus H.J., Kersten, Marie-Jose, Miedema, Frank

“…The classic view of CLL as a static disease has recently been challenged by the first in vivo CLL cell kinetics study (Messmer BT, et al. J Clin Invest. 2005)…”
Get full text

High Rates of Molecular Response and Low Incidence of Mutations in Patients Treated with Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated with a Dose-Escalated Combination of Imatinib and Cytarabin by Cornelissen, Jan J., Valk, Peter, Verhoef, Gregor E.G., Smit, Wim M., van Marwijk-Kooij, Marinus, Wittebol, Shulamit, van Oers, Marinus H.J., Kluin-Nelemans, Hanneke C., Lowenberg, Bob, Willemze, Roelof, Schattenberg, Antonius V.M.B., Ossenkoppele, Gert

“…Imatinib mesylate (IM) induces a high rate of cytogenetic remissions in first chronic phase CML, but molecular remissions are rare. A recent phase II study…”
Get full text

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Updated Analysis of the Randomized Phase III Study HOVON 24 MM by Sonneveld, Pieter, van der Holt, Bronno, Segeren, Christine, Vellenga, Edo, Raymakers, Reinier, Verhoef, Gregor, Schaafsma, Ron, van Oers, Marinus, Weijermans, Pierre, Fibbe, Wim, Wittebol, Shulamit, van Marwijk, Marinus, Biesma, Douwe, Baars, Joke, Schouten, Harry, Westveer, Petra, Steijaert, Monique, Lokhorst, Henk

“…In 1995 HOVON started a prospective randomized multicenter trial to compare the efficacy of intensified treatment followed by myelo-ablative therapy and stem…”
Get full text